Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Skin Diseases Clear all
Active, not recruiting Phase 2 Interventional

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06046729
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Eltrekibart, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

NCT07065773
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Trichostatin A
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Denver, Colorado • New Brighton, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

NCT00730405
View directory record Official record
Conditions
Onychomycosis
Interventions
Albaconazole 100mg, Albaconazole 200mg, Albaconazole 400mg, Placebo 400 mg
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

NCT02394340
View directory record Official record
Conditions
Tinea Pedis, Tinea Cruris
Interventions
Omeprazole 40 mg, Luliconazole Cream 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

NCT02781818
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Jul 23, 2026, 5:40 AM EDT
Completed No phase listed Observational

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140
View directory record Official record
Conditions
Latent Tuberculosis Infection, Tuberculosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
21,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 23, 2026, 5:40 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

BIO-SEE: Bioburden Imaging Outcome Study for Equivalence Evaluation

NCT07611318
View directory record Official record
Conditions
DFU, VLU, Surgical Wound, Wounds, Pressure Injuries
Interventions
cureVision cV
Diagnostic Test
Lead sponsor
Capsicure, LLC
Network
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02452918
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Oritavancin, Warfarin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail

NCT02798380
View directory record Official record
Conditions
Onychomycosis
Interventions
HTS-519 Insert
Drug
Lead sponsor
Hallux, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

NCT04414514
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib 1.5% Cream
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus

NCT00960089
View directory record Official record
Conditions
Onychomycosis
Interventions
LIQUICURE
Device
Lead sponsor
Chesson Laboratory Associates, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
4
States / cities
Cary, North Carolina • Chapel Hill, North Carolina • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jul 23, 2026, 5:40 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Role of Bacterial Toxins in Human Skin Disease

NCT02910791
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

NCT01252732
View directory record Official record
Conditions
Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

NCT00513799
View directory record Official record
Conditions
Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
Interventions
Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute), Intensive education on personal hygiene
Drug · Genetic · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

A Study of Econazole Foam 1% in Athlete's Foot

NCT00768599
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Cream 1%, Econazole Nitrate Foam 1%, Vehicle Foam
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
San Diego, California • Clinton Township, Michigan • Fridley, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT04762277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

NCT02812771
View directory record Official record
Conditions
Onychomycosis
Interventions
Efinaconazole
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 5:40 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

NCT05470322
View directory record Official record
Conditions
Hidradenitis Suppurativa, Scarring
Interventions
Er: YAG laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cumulative Irritation Test

NCT00680095
View directory record Official record
Conditions
Onychomycosis
Interventions
AN2690, AN2690 Solution, Vehicle, Sodium Lauryl Sulfate, 0.5%
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 23, 2026, 5:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
BFB759, Placebo for BFB759
Biological · Other
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Encino, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 5:40 AM EDT